Serum Nitric Oxide, Endothelin-1 Correlates Post-Procedural Major Adverse Cardiovascular Events among Patients with Acute STEMI
- PMID: 39841755
- PMCID: PMC11834733
- DOI: 10.36660/abc.20240248
Serum Nitric Oxide, Endothelin-1 Correlates Post-Procedural Major Adverse Cardiovascular Events among Patients with Acute STEMI
Abstract
Background: ST-segment elevation myocardial infarction (STEMI) is a common and severe form of acute myocardial infarction (AMI).
Objectives: The study aimed to investigate the relationship between serum nitric oxide (NO) and endothelin-1 (ET-1) levels with the severity of STEMI and their predictive value for major adverse cardiovascular events (MACE) within one year after percutaneous coronary intervention (PCI) in STEMI patients.
Methods: The retrospective study was conducted on 269 STEMI patients who underwent PCI. The patients were categorized into two groups: those who developed MACE (112 cases) and those who did not (157 cases) within one year. NO and ET1 levels were measured in collected serum using enzyme-linked immunosorbent assay. Receive-operating characteristics (ROC) curve was used to analyze the prognostic potential of NO and ET1 individually and in combination, p<0.05 was considered statistically significant.
Results: Significant differences were noted between the two groups concerning age, Killip classification, left ventricular ejection fraction, cardiac troponin I (cTnI), creatine kinase-MB (CK-MB), as well as serum NO and ET-1 levels. The study observed that patients who developed MACE had lower serum NO and higher ET-1 levels upon admission. Further analysis revealed a significant inverse relationship between serum NO and ET-1 levels and the severity of myocardial infarction. A combined detection model, -0.082 * NO + 0.059 * ET-1, demonstrated promising prognostic value for the occurrence of MACE within one year post-PCI.
Conclusions: Serum NO and ET-1 levels serve as valuable prognostic markers for MACE in STEMI patients undergoing PCI, exhibiting a strong correlation with AMI severity.
Fundamento: O infarto do miocárdio com elevação do segmento ST (IAMCSST) é uma forma comum e grave de infarto agudo do miocárdio (IAM).
Objetivos: O estudo teve como objetivo investigar a relação entre os níveis séricos de óxido nítrico (NO) e endotelina-1 (ET-1) com a gravidade do IAMCSST e seu valor preditivo para eventos cardiovasculares adversos maiores (MACE) dentro de um ano após intervenção coronária percutânea (ICP) em pacientes com IAMCSST.
Métodos: O estudo retrospectivo foi conduzido em 269 pacientes com IAMCSST submetidos a ICP. Os pacientes foram categorizados em dois grupos: aqueles que desenvolveram MACE (112 casos) e aqueles que não desenvolveram (157 casos) em um ano. Os níveis de NO e ET-1 foram medidos no soro coletado usando ensaio imunoenzimático. A curva ROC (Receive-Operating Characteristics) foi usada para analisar o potencial prognóstico de NO e ET-1 individualmente e em combinação, p<0,05 foi considerado estatisticamente significativo.
Resultados: Foram observadas diferenças significativas entre os dois grupos em relação à idade, classificação de Killip, fração de ejeção do ventrículo esquerdo, troponina I cardíaca (cTnI), creatina quinase-MB (CK-MB), bem como níveis séricos de NO e ET-1. O estudo observou que pacientes que desenvolveram MACE tinham níveis séricos mais baixos de NO e níveis mais altos de ET-1 na admissão. Análises posteriores revelaram uma relação inversa significativa entre os níveis séricos de NO e ET-1 e a gravidade do infarto do miocárdio. Um modelo de detecção combinado, -0,082 * NO + 0,059 * ET-1, demonstrou valor prognóstico promissor para a ocorrência de MACE dentro de um ano após a ICP.
Conclusões: Os níveis séricos de NO e ET-1 servem como marcadores prognósticos valiosos para MACE em pacientes com STEMI submetidos a ICP, exibindo uma forte correlação com a gravidade do IAM.
Figures








Similar articles
-
Predictive value of triglyceride glucose index combined with neutrophil-to-lymphocyte ratio for major adverse cardiac events after PCI for acute ST-segment elevation myocardial infarction.Sci Rep. 2024 Jun 2;14(1):12634. doi: 10.1038/s41598-024-63604-9. Sci Rep. 2024. PMID: 38824158 Free PMC article.
-
Remote Ischemic Postconditioning (RIPC) of the Upper Arm Results in Protection from Cardiac Ischemia-Reperfusion Injury Following Primary Percutaneous Coronary Intervention (PCI) for Acute ST-Segment Elevation Myocardial Infarction (STEMI).Med Sci Monit. 2018 Feb 19;24:1017-1026. doi: 10.12659/msm.908247. Med Sci Monit. 2018. PMID: 29456238 Free PMC article. Clinical Trial.
-
In-hospital major adverse cardiovascular events after primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: a retrospective study under the China chest pain center (standard center) treatment system.BMC Cardiovasc Disord. 2023 Apr 17;23(1):198. doi: 10.1186/s12872-023-03214-x. BMC Cardiovasc Disord. 2023. PMID: 37069503 Free PMC article.
-
Usefulness of High Sensitivity Troponin T to Predict Long-Term Left Ventricular Dysfunction After ST-Elevation Myocardial Infarction.Am J Cardiol. 2020 Nov 1;134:8-13. doi: 10.1016/j.amjcard.2020.07.060. Epub 2020 Aug 15. Am J Cardiol. 2020. PMID: 32933755
-
Predictive value of neutrophil to lymphocyte ratio in patients with acute ST segment elevation myocardial infarction after percutaneous coronary intervention: a meta-analysis.BMC Cardiovasc Disord. 2018 May 2;18(1):75. doi: 10.1186/s12872-018-0812-6. BMC Cardiovasc Disord. 2018. PMID: 29716535 Free PMC article. Review.
References
-
- Cowper PA, Knight JD, Davidson-Ray L, Peterson ED, Wang TY, Mark DB, et al. Acute and 1-Year Hospitalization Costs for Acute Myocardial Infarction Treated with Percutaneous Coronary Intervention: Results from the TRANSLATE-ACS Registry. J Am Heart Assoc . 2019;8(8):e011322. doi: 10.1161/JAHA.118.011322. - DOI - PMC - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous